These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 31346928

  • 1. Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib.
    Kuo CS, Huang CH, Liu CY, Pavlidis S, Ko HW, Chung FT, Lin TY, Wang CL, Guo YK, Yang CT.
    Target Oncol; 2019 Aug; 14(4):433-440. PubMed ID: 31346928
    [Abstract] [Full Text] [Related]

  • 2. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K.
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [Abstract] [Full Text] [Related]

  • 3. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T, Kasai T, Okada M, Nakachi I, Soda S, Arai R, Takigami A, Sata M.
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [Abstract] [Full Text] [Related]

  • 4. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y, Hao X, Xing P, Hu X, Wang Y, Li T, Zhang J, Xu Z, Li J.
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [Abstract] [Full Text] [Related]

  • 5. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
    Dal Maso A, Lorenzi M, Ferro A, Pilotto S, Cecere F, Follador A, Polo V, Del Conte A, Sartori G, Giavarra M, Scattolin D, Indraccolo S, Frega S, De Maglio G, Menis J, Bonanno L, Calabrese F, Guarneri V, Conte P, Pasello G.
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [Abstract] [Full Text] [Related]

  • 6. The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.
    Buder A, Hochmair MJ, Filipits M.
    Target Oncol; 2021 Jan; 16(1):77-84. PubMed ID: 33270169
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L, Fan J, Qian R, Luo P, Zhang J.
    Int J Cancer; 2019 Jul 01; 145(1):284-294. PubMed ID: 30613959
    [Abstract] [Full Text] [Related]

  • 8. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C, Nie W, Guo J, Xiong A, Zhong H, Chu T, Zhong R, Xu J, Lu J, Zheng X, Zhang B, Shen Y, Pan F, Han B, Zhang X.
    Respir Res; 2021 May 11; 22(1):145. PubMed ID: 33975616
    [Abstract] [Full Text] [Related]

  • 9. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
    Chiang CL, Huang HC, Shen CI, Luo YH, Chen YM, Chiu CH.
    Target Oncol; 2020 Aug 11; 15(4):503-512. PubMed ID: 32696212
    [Abstract] [Full Text] [Related]

  • 10. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
    Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Tamiya N, Goto Y, Kanda H, Chihara Y, Kunimatsu Y, Katayama Y, Iwasaku M, Tokuda S, Takayama K.
    Target Oncol; 2023 Sep 11; 18(5):657-665. PubMed ID: 37610516
    [Abstract] [Full Text] [Related]

  • 11. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
    Sakai K, Takahama T, Shimokawa M, Azuma K, Takeda M, Kato T, Daga H, Okamoto I, Akamatsu H, Teraoka S, Ono A, Ohira T, Yokoyama T, Yamamoto N, Nakagawa K, Nishio K.
    Mol Oncol; 2021 Jan 11; 15(1):126-137. PubMed ID: 33131198
    [Abstract] [Full Text] [Related]

  • 12. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T, Azuma K, Shimokawa M, Takeda M, Ishii H, Kato T, Saito H, Daga H, Tsuboguchi Y, Okamoto I, Otsubo K, Akamatsu H, Teraoka S, Takahashi T, Ono A, Ohira T, Yokoyama T, Sakai K, Yamamoto N, Nishio K, Nakagawa K.
    Cancer; 2020 Jan 01; 126(9):1940-1948. PubMed ID: 32022929
    [Abstract] [Full Text] [Related]

  • 13. Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR-TKIs.
    Ninomaru T, Hata A, Kokan C, Okada H, Tomimatsu H, Ishida J.
    Thorac Cancer; 2021 Mar 01; 12(6):746-751. PubMed ID: 33475261
    [Abstract] [Full Text] [Related]

  • 14. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Ichihara E, Hotta K, Ninomiya K, Kubo T, Ohashi K, Rai K, Tanaka H, Tabata M, Maeda Y, Kiura K.
    Lung Cancer; 2019 Jun 01; 132():54-58. PubMed ID: 31097094
    [Abstract] [Full Text] [Related]

  • 15. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K.
    Thorac Cancer; 2020 Jan 01; 11(1):140-149. PubMed ID: 31758670
    [Abstract] [Full Text] [Related]

  • 16. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M.
    Target Oncol; 2019 Feb 01; 14(1):75-83. PubMed ID: 30539501
    [Abstract] [Full Text] [Related]

  • 17. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
    Nakashima K, Kimura M, Akamatsu H, Daga H, Imai H, Taira T, Ko R, Hisamatsu Y, Nishino K, Sugimoto T, Miyashita Y, Takahashi T, et al.
    Jpn J Clin Oncol; 2019 Jul 01; 49(7):671-675. PubMed ID: 30920616
    [Abstract] [Full Text] [Related]

  • 18. The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC.
    Tamiya M, Tamiya A, Okamoto N, Taniguchi Y, Nishino K, Atagi S, Hirashima T, Imamura F, Kumagai T, Suzuki H.
    Sci Rep; 2021 May 05; 11(1):9629. PubMed ID: 33953280
    [Abstract] [Full Text] [Related]

  • 19. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
    Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC, FLAURA Investigators.
    N Engl J Med; 2020 Jan 02; 382(1):41-50. PubMed ID: 31751012
    [Abstract] [Full Text] [Related]

  • 20. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
    Remon J, Steuer CE, Ramalingam SS, Felip E.
    Ann Oncol; 2018 Jan 01; 29(suppl_1):i20-i27. PubMed ID: 29462255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.